1. Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Earlyonset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 2014;370:911-20.
2. Elkan PN, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 2014;370: 921-31.
3. Van Montfrans JM, Hartman EAR, Braun KPJ, Hennekam EAM, Hak EA, Nederkoorn PJ, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford) 2016;55:902-10.
4. Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol 2018;2: 569-78.
5. Lee PY, Kellner ES, Huang Y, Furutani E, Huang Z, Bainter W, et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). J Allergy Clin Immunol 2020;2:1664-72.
6. Hashem H, Kumar AR, M€uller I, Babor F, Bredius R, Dalal J, et al. Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood 2017;130:2682-8.
7. Carmona-Rivera C, Khaznadar SS, Shwin KW, Irizarry-Caro JA, O’Neil LJ, Liu Y, et al. Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2. Blood 2019;134:395-406.
8. Kaljas Y, Liu C, Skaldin M, Wu C, Zhou Q, Lu Y, et al. Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells. Cell Mol Life Sci 2017;74:555-70.
9. Insalaco A, Moneta GM, Pardeo M, Caiello I, Messia V, Bracaglia C, et al. Variable clinical phenotypes and relation of interferon signature with disease activity in ADA2 deficiency. J Rheumatol 2019;46:523-6.
10. Skrabl-Baumgartner A, Plecko B, Schmidt WM, K€onig N, Hershfield M, GruberSedlmayr U, et al. Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation. Pediatr Rheumatol 2017;15:67.
11. Belot A, Wassmer E, Twilt M, Lega J-C, Zeef LA, Oojageer A, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr Rheumatol Online J 2014;12:44.
12. Iwaki-egawa S, Namiki C, Watanabe Y. Adenosine deaminase 2 from chicken liver: purification, characterization, and N-terminal amino acid sequence. Comp Biochem Physiol 2004;137:247-54.
13. Kawashima Y, Miyata J, Watanabe T, Shioya J, Arita M, Ohara O. Proteogenomic analyses of cellular lysates using a phenol-guanidinium thiocyanate reagent. J Proteome Res 2019;18:301-8.
14. Keino D, Kondoh K, Sudo A, Ohyama R, Morimoto M, Nihira H, et al. Successful treatment with cyclosporine and etanercept for deficiency of adenosine deaminase 2. Scand J Rheumatol 2020 Jul 28 [E-pub ahead of print].
15. Nihira H, Nakagawa K, Izawa K, Kawai T, Yasumi T, Nishikomori R, et al. Fever of unknown origin with rashes in early infancy is indicative of adenosine deaminase type 2 deficiency. Scand J Rheumatol 2018;47:170-2.
16. Rama M, Duflos C, Melki I, Bessis D, Bonhomme A, Martin H, et al. A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience. Eur J Hum Genet 2018;26:960-71.
17. Kim H, De Jesus AA, Brooks SR, Liu Y, Huang Y, Vantries R, et al. Development of a validated interferon score using nanostring technology. J Interferon Cytokine Res 2018;38:171-85.
18. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MGE, et al. Coordinate overexpression of interferon-alpha–induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958-67.
19. Liu M, Liu J, Hao S, Wu P, Zhang X, Xiao Y, et al. Higher activation of the interferongamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity. Clin Rheumatol 2018;37:2675-84.
20. Mehta NN, Teague HL, Swindell WR, Baumer Y, Ward NL, Xing X, et al. IFN-g and TNF-a synergism may provide a link between psoriasis and inflammatory atherogenesis. Sci Rep 2017;7:1-11.
21. Ivashkiv LB. IFNg: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol 2018;18:545-58.
22. Prencipe G, Caiello I, Pascarella A, Grom AA, Bracaglia C, Chatel L, et al. Neutralization of IFN-g reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J Allergy Clin Immunol 2018;141:1439-49.
23. Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview. J Exp Med 2016;213:2527-38.
24. Rice GI, Melki I, Fremond ML, Briggs TA, Rodero MP, Kitabayashi N, et al. Assessment of type I interferon signaling in pediatric inflammatory disease. J Clin Immunol 2017;37:123-32.
25. de Jesus AA, Hou Y, Brooks S, Malle L, Biancotto A, Huang Y, et al. Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. J Clin Invest 2020;130:1669-82.
26. Rice GI, Forte GMA, Szynkiewicz M, Chase DS, Aeby A, Abdel-Hamid MS, et al. Assessment of interferon-related biomarkers in AGS associated with mutations in Trex1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a control study. Lancet Neurol 2013;12:1159-69.
27. Montealegre Sanchez GA, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest 2018;128:3041-52.
28. Landolt-Marticorena C, Bonventi G, Lubovich A, Ferguson C, Unnithan T, Su J, et al. Lack of association between the interferon-a signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009;68:1440-6.
29. Feng X, Wu H, Grossman JM, Hanvivadhanakul P, Fitzgerald JD, Park GS, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951-62.
30. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264: 1415-21.
31. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004;117:1281-3.
32. Hu X, Herrero C, Li WP, Antoniv TT, Falck-Pedersen E, Koch AE, et al. Sensitization of IFN-g Jak-STAT signaling during macrophage activation. Nat Immunol 2002;3:859-66.
33. Honda-Ozaki F, Terashima M, Niwa A, Saiki N, Kawasaki Y, Ito H, et al. Pluripotent stem cell model of Nakajo-Nishimura syndrome untangles proinflammatory pathways mediated by oxidative stress. Stem Cell Reports 2018;10:1835-50.
34. Qiao Y, Giannopoulou EG, Chan CH, Park S-H, Gong S, Chen J, et al. Synergistic activation of inflammatory cytokine genes by interferon-g-induced chromatin remodeling and toll-like receptor signaling. Immunity 2013;39:454-69.
35. Haider AS, Cohen J, Fei J, Zaba LC, Cardinale I, Toyoko K, et al. Insights into gene modulation by therapeutic TNF and IFNg antibodies: TNF regulates IFNg production by T cells and TNF-regulated genes linked to psoriasis transcriptome. J Invest Dermatol 2008;128:655-66.
36. Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-a therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-b. J Exp Med 2007;204:33-9.
37. Ombrello AK, Bethesda, Qin J, Bethesda, Hoffmann PM, Bethesda, et al. Treatment strategies for deficiency of adenosine deaminase 2. N Engl J Med 2019; 380:1582-4.
38. Keer N, Hershfield M, Caskey T, Unizony S. Novel compound heterozygous variants in CECR1 gene associated with childhood onset polyarteritis nodosa and deficiency of ADA2. Rheumatology (Oxford) 2016;55:1145-7.
39. Thibaudeau TA, Smith DM. A practical review of proteasome pharmacology. Pharmacol Rev 2019;71:170-97.
40. Lieberman OJ, Frier MD, McGuirt AF, Griffey CJ, Rafikian E, Yang M, et al. Celltype-specific regulation of neuronal intrinsic excitability by macroautophagy. Elife 2020;9:1-39.